Literature DB >> 6501510

High-performance liquid chromatographic separation of cadralazine from its potential metabolites and degradation products. Quantitation of the drug in human plasma and urine.

T Crolla, F Santini, M Visconti, G Pifferi.   

Abstract

The chromatographic behaviour of cadralazine and its potential metabolites and degradation products with respect to pH, buffer molarity and composition of eluent is described. A selective method with an adequate sensitivity for the determination of the drug in human plasma and urine is also reported. The method includes extraction of biological fluids with chloroform and the analysis of extracts on a reversed-phase column with isocratic elution and detection at 254 nm. The method has been applied to the analysis of plasma and urine of a patient administered a single oral dose of 30 mg of cadralazine.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6501510     DOI: 10.1016/0378-4347(84)80075-4

Source DB:  PubMed          Journal:  J Chromatogr


  1 in total

1.  Pharmacokinetics of cadralazine in hypertensive patients.

Authors:  G Leonetti; J Parini; M Visconti; R Gradnik
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1988 Oct-Dec       Impact factor: 2.441

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.